Prostate Cancer Channel
-
Grant’s Anatomy Lab
This customizable online gross human anatomy lab manual is based on the renowned texts Grant’s Dissector and Grant’s Atlas of Anatomy. Instructors can easily edit the current Grant's Dissector content to best suit the needs of their specific anatomy and physiology courses and students.
-
Visible Body
This award-winning 3D interactive anatomy visualization and learning tool challenges students to explore and understand the human body from head to toe via interactive 3D models, animations, quizzes, augmented reality, and more. Covers anatomy, physiology, muscles, the skeleton and circulatory system.
-
LWW Health Library – Anatomical Sciences Collection
This online solution, with Lippincott® content at its core, is built for optimal learning and accessibility. Anatomy and physiology students and faculty receive access to a must-have collection of authoritative texts, multimedia resources, and teaching and learning tools.
Featured Content
A collection of timely studies, news, treatment options and more is presented in this concise, invaluable resource.
Resource Library
Choosing a Practice or Choosing a Partner?
Salary Survey reviews options and salary by state for making the transition to private practice…March 2019, AAOS Career Center Feature
Factors Motivating Medical Students in Selecting a Career Specialty: Relevance for a Robust Orthopaedic Pipeline
Research Article. Journal of the American Academy of Orthopaedic Surgeons.
Two Year or Four Year Fellowship
The Impact on early stage career growth and salary. July 2019, AAOS Career Center Feature.
Surveys
FDA Approves Enzalutamide for Non-Metastatic Castration-Resistant Prostate Cancer
The FDA approved a supplemental New Drug Application (sNDA) for enzalutamide, following FDA Priority Review designation, based on results from the phase III PROSPER trial. The FDA action broadens the indication for enzalutamide to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC.
FDA Approves Enzalutamide for Non-Metastatic Castration-Resistant Prostate Cancer
The FDA approved a supplemental New Drug Application (sNDA) for enzalutamide, following FDA Priority Review designation, based on results from the phase III PROSPER trial. The FDA action broadens the indication for enzalutamide to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC.
More Surveys
- Salary Survey
- Work-Life Survey
- Job Seeker Survey
Prostate Cancer Channel
Brought to you by Oncology Times
A collection of timely studies, news, treatment options and more is presented in this concise, invaluable resource.
Resource Library
Choosing a Practice or Choosing a Partner?
Salary Survey reviews options and salary by state for making the transition to private practice…March 2019, AAOS Career Center Feature
Factors Motivating Medical Students in Selecting a Career Specialty: Relevance for a Robust Orthopaedic Pipeline
Research Article. Journal of the American Academy of Orthopaedic Surgeons.
Two Year or Four Year Fellowship
The Impact on early stage career growth and salary. July 2019, AAOS Career Center Feature.
Surveys
FDA Approves Enzalutamide for Non-Metastatic Castration-Resistant Prostate Cancer
The FDA approved a supplemental New Drug Application (sNDA) for enzalutamide, following FDA Priority Review designation, based on results from the phase III PROSPER trial. The FDA action broadens the indication for enzalutamide to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC.
FDA Approves Enzalutamide for Non-Metastatic Castration-Resistant Prostate Cancer
The FDA approved a supplemental New Drug Application (sNDA) for enzalutamide, following FDA Priority Review designation, based on results from the phase III PROSPER trial. The FDA action broadens the indication for enzalutamide to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC.
More Surveys
- Salary Survey
- Work-Life Survey
- Job Seeker Survey
Prostate Cancer Channel
Brought to you by Oncology Times
Loading